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Background: Patients with acute coronary syndromes (ACS) who undergo stent implantation have increased on-treatment platelet reactivity (HPR), 
which has been associated with post-procedural thrombotic events.
Objectives and Methods: ADAPT-DES was a prospective multicenter observational study of 8,575 unselected patients undergoing drug-eluting 
stent implantation; routine platelet function testing was performed with the VerifyNow P2Y12 assay following clopidogrel loading. We sought to 
examine the association between HPR and stent thrombosis (ST) in patients with and without ACS enrolled in ADAPT-DES.
Results: 4,435 patients (51.7%) had ACS. After clopidogrel loading patients with ACS had higher platelet reactivity units (PRU) (193.8 vs. 181.7, 
p<0.0001). Of the 39 total 30-day definite/probable ST, 30 (76.9%) occurred among patients with ACS; as such, 30-day ST was more frequent 
among ACS patients (Figure). HPR was independently associated with 30-day ST in ACS (adjusted HR for PRU>208 = 3.91 (95% CI 1.51-10.11), 
p=0.005), whereas the relationship was weaker and non-significant in non-ACS (adjusted HR for PRU>208 = 1.49 (95% CI 0.35-6.36), p=0.59). HPR 
had overall low specificity for 30-day ST, even among ACS patients (54.7%).
Conclusions: Most ST events within 30 days after DES occur in patients with ACS, and HPR is strongly associated with ST in ACS. However, due in 
part to low overall event rates, the predictive capacity of HPR for ST is modest, and appears largely confined to patients with ACS.
 
